We are a Tucson, Arizona based non-profit organization of accredited investors who seek opportunities to invest in Southwest regional startup or early stage companies.
Present your Company
The DESERT ANGELS ™ welcomes applications from startup or early stage companies. We evaluate applications on an ongoing basis and meet monthly from September through June.
Present your company
Become a member
As a vibrant, growing organization, the DESERT ANGELS ™ welcomes new members. If you are an accredited investor with a tenacious appetite for helping early-stage companies succeed, we’d love to get to know you better at an upcoming dinner meeting.
It is safe to say that there would have been no Calimmune without the early support of the Desert Angels.
Many members of the DA share our passion and see the potential for gene therapy to transform healthcare and liberate patients from chronic and incurable diseases. Their investments have helped us grow this company to what it is today. We truly hope Calimmune’s work will be life-changing for the people we plan to serve and the investors that supported us.
Salutaris Medical Devices, Inc. announced the first subject was treated in a multi-center clinical trial investigating the use of its ophthalmic brachytherapy device to treat neovascular Age-related Macular Degeneration (nAMD) on May 23, 2018. Dr. Gregg Kokame, Principal Investigator (PI) at the clinical site in Honolulu successfully performed the first procedure using the SMD-DA device on May […]
Regenesis Biomedical, a Scottsdale-based medical device company, has initiated a multi-center, randomized clinical trial assessing the Provant® Therapy System for relieving symptoms of painful diabetic distal symmetric peripheral neuropathy (DSPN). Painful neuropathy affects over 3 million people in the United States, resulting in nerve damage in the extremities such as tingling, numbness, pain and sensitivity […]
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products and services, today announced a non‑exclusive license and supply agreement (“Agreement”) that will enable Firalis to commercialize a next‑generation sequencing (NGS)‑based theranostic product and services to […]